← Leaderboards
Catherine Cukras
National Eye Institute
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at National Eye Institute
Same institution · by research overlap
Others in their field
Top investigators on “Participant”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Jeffrey P Krischer · University Of South Florida$407,724,307
- Lawrence Corey · Fred Hutchinson Cancer Center$333,313,234
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Gary D Acton · University Of California-Davis$320,373,312
- Albert Lazzarini · California Institute Of Technology$300,431,866
Research focus
ParticipantRetinaVisual AcuityEnrollmentBlindnessSeveritiesAffectDesignPrimary OutcomeMaculaThickSecondary OutcomeOutcome MeasureVisitInvestigationSafetyMicrogliaInflammatoryVisionOralClinical TrialsPharmaceutical PreparationsAdverse EventToxic Effect
Grant awards (87)
Genotype - phenotype Study of Patients with Plaquenil-induced Retinal Toxicity,$198,004
ZIA · FY2025 · EY · contact PI
Longitudinal Investigation of Dark Adaptation in Participants with AMD$151,203
ZIA · FY2025 · EY · contact PI
A Survey study of Retinitis Pigmentosa (RP) clinical measures and repeatability testing of potential outcome measures$90,002
ZIA · FY2025 · EY · contact PI
Eval. of Minocycline as a Microglia Inhibitor in Tx of CRVO and BRVO$90,002
ZIA · FY2025 · EY · contact PI
An Investigation of Vitamin A Palmitate Supplementation in Patients withAMD and/or Reticular Pseudodrusen (RPD) and Delayed Dark Adaptation$39,601
ZIA · FY2025 · EY · contact PI
Pilot Study to Evaluate Oral Minocycline in the Treatment of Cystoid Macular Edema Associated with Retinitis Pigmentosa$21,600
ZIA · FY2025 · EY · contact PI
Adaptive Optics Imaging of Outer Retinal Diseases$18,000
ZIA · FY2025 · EY · contact PI
Longitudinal Investigation of Dark Adaptation in Participants with AMD$313,234
ZIA · FY2024 · EY · contact PI
Genotype - phenotype Study of Patients with Plaquenil-induced Retinal Toxicity,$223,738
ZIA · FY2024 · EY · contact PI
A Survey study of Retinitis Pigmentosa (RP) clinical measures and repeatability testing of potential outcome measures$101,699
ZIA · FY2024 · EY · contact PI
Eval. of Minocycline as a Microglia Inhibitor in Tx of CRVO and BRVO$101,699
ZIA · FY2024 · EY · contact PI
An Investigation of Vitamin A Palmitate Supplementation in Patients withAMD and/or Reticular Pseudodrusen (RPD) and Delayed Dark Adaptation$44,748
ZIA · FY2024 · EY · contact PI
Pilot Study to Evaluate Oral Minocycline in the Treatment of Cystoid Macular Edema Associated with Retinitis Pigmentosa$24,408
ZIA · FY2024 · EY · contact PI
Adaptive Optics Imaging of Outer Retinal Diseases$20,340
ZIA · FY2024 · EY · contact PI
Medical Retina Fellowship$1,070,068
ZIE · FY2023 · EY · contact PI
Longitudinal Investigation of Dark Adaptation in Participants with AMD$296,386
ZIA · FY2023 · EY · contact PI
Genotype - phenotype Study of Patients with Plaquenil-induced Retinal Toxicity,$230,950
ZIA · FY2023 · EY · contact PI
A Survey study of Retinitis Pigmentosa (RP) clinical measures and repeatability testing of potential outcome measures$96,229
ZIA · FY2023 · EY · contact PI
Eval. of Minocycline as a Microglia Inhibitor in Tx of CRVO and BRVO$96,229
ZIA · FY2023 · EY · contact PI
An Investigation of Vitamin A Palmitate Supplementation in Patients withAMD and/or Reticular Pseudodrusen (RPD) and Delayed Dark Adaptation$42,341
ZIA · FY2023 · EY · contact PI
Pilot Study to Evaluate Oral Minocycline in the Treatment of Cystoid Macular Edema Associated with Retinitis Pigmentosa$23,095
ZIA · FY2023 · EY · contact PI
Adaptive Optics Imaging of Outer Retinal Diseases$19,246
ZIA · FY2023 · EY · contact PI
Medical Retina Fellowship$997,688
ZIE · FY2022 · EY · contact PI
Genotype - phenotype Study of Patients with Plaquenil-induced Retinal Toxicity,$318,560
ZIA · FY2022 · EY · contact PI
Longitudinal Investigation of Dark Adaptation in Participants with AMD$269,551
ZIA · FY2022 · EY · contact PI
A Survey study of Retinitis Pigmentosa (RP) clinical measures and repeatability testing of potential outcome measures$87,517
ZIA · FY2022 · EY · contact PI
Eval. of Minocycline as a Microglia Inhibitor in Tx of CRVO and BRVO$87,517
ZIA · FY2022 · EY · contact PI
An Investigation of Vitamin A Palmitate Supplementation in Patients withAMD and/or Reticular Pseudodrusen (RPD) and Delayed Dark Adaptation$38,507
ZIA · FY2022 · EY · contact PI
Pilot Study to Evaluate Oral Minocycline in the Treatment of Cystoid Macular Edema Associated with Retinitis Pigmentosa$21,004
ZIA · FY2022 · EY · contact PI
Adaptive Optics Imaging of Outer Retinal Diseases$17,503
ZIA · FY2022 · EY · contact PI
Medical Retina Fellowship$831,533
ZIE · FY2021 · EY · contact PI
Genotype - phenotype Study of Patients with Plaquenil-induced Retinal Toxicity,$282,349
ZIA · FY2021 · EY · contact PI
Longitudinal Investigation of Dark Adaptation in Participants with AMD$238,911
ZIA · FY2021 · EY · contact PI
A Survey study of Retinitis Pigmentosa (RP) clinical measures and repeatability testing of potential outcome measures$93,082
ZIA · FY2021 · EY · contact PI
Eval. of Minocycline as a Microglia Inhibitor in Tx of CRVO and BRVO$89,979
ZIA · FY2021 · EY · contact PI
An Investigation of Vitamin A Palmitate Supplementation in Patients withAMD and/or Reticular Pseudodrusen (RPD) and Delayed Dark Adaptation$34,130
ZIA · FY2021 · EY · contact PI
Pilot Study to Evaluate Oral Minocycline in the Treatment of Cystoid Macular Edema Associated with Retinitis Pigmentosa$18,616
ZIA · FY2021 · EY · contact PI
Adaptive Optics Imaging of Outer Retinal Diseases$15,514
ZIA · FY2021 · EY · contact PI
Longitudinal Investigation of Dark Adaptation in Participants with AMD$131,620
ZIA · FY2020 · EY · contact PI
Eval. of Minocycline as a Microglia Inhibitor in Tx of CRVO and BRVO$116,995
ZIA · FY2020 · EY · contact PI
A Survey study of Retinitis Pigmentosa (RP) clinical measures and repeatability testing of potential outcome measures$102,371
ZIA · FY2020 · EY · contact PI
Medical Retina Fellowship$87,746
ZIE · FY2020 · EY · contact PI
An Investigation of Vitamin A Palmitate Supplementation in Patients withAMD and/or Reticular Pseudodrusen (RPD) and Delayed Dark Adaptation$73,122
ZIA · FY2020 · EY · contact PI
Genotype - phenotype Study of Patients with Plaquenil-induced Retinal Toxicity,$32,174
ZIA · FY2020 · EY · contact PI
Pilot Study to Evaluate Oral Minocycline in the Treatment of Cystoid Macular Edema Associated with Retinitis Pigmentosa$32,174
ZIA · FY2020 · EY · contact PI
Medical Retina Fellowship$107,407
ZIE · FY2019 · EY · contact PI
Longitudinal Investigation of Dark Adaptation in Participants with AMD$107,407
ZIA · FY2019 · EY · contact PI
Eval. of Minocycline as a Microglia Inhibitor in Tx of CRVO and BRVO$99,145
ZIA · FY2019 · EY · contact PI
A Survey study of Retinitis Pigmentosa (RP) clinical measures and repeatability testing of potential outcome measures$82,621
ZIA · FY2019 · EY · contact PI
Pilot Study to Evaluate Oral Minocycline in the Treatment of Cystoid Macular Edema Associated with Retinitis Pigmentosa$57,835
ZIA · FY2019 · EY · contact PI
An Investigation of Vitamin A Palmitate Supplementation in Patients withAMD and/or Reticular Pseudodrusen (RPD) and Delayed Dark Adaptation$55,081
ZIA · FY2019 · EY · contact PI
Genotype - phenotype Study of Patients with Plaquenil-induced Retinal Toxicity,$30,294
ZIA · FY2019 · EY · contact PI
Evaluation of Dextromethorphan as a Microglia Inhibitor in the treatment of DME$30,294
ZIA · FY2019 · EY · contact PI
Medical Retina Fellowship$160,529
ZIE · FY2018 · EY · contact PI
Longitudinal Investigation of Dark Adaptation in Participants with AMD$78,904
ZIA · FY2018 · EY · contact PI
Eval. of Minocycline as a Microglia Inhibitor in Tx of CRVO and BRVO$70,742
ZIA · FY2018 · EY · contact PI
Pilot Study to Evaluate Oral Minocycline in the Treatment of Cystoid Macular Edema Associated with Retinitis Pigmentosa$57,138
ZIA · FY2018 · EY · contact PI
Evaluation of Dextromethorphan as a Microglia Inhibitor in the treatment of DME$29,929
ZIA · FY2018 · EY · contact PI
Genotype - phenotype Study of Patients with Plaquenil-induced Retinal Toxicity,$29,929
ZIA · FY2018 · EY · contact PI
Medical Retina Fellowship$168,020
ZIE · FY2017 · EY · contact PI
Longitudinal Investigation of Dark Adaptation in Participants with AMD$76,134
ZIA · FY2017 · EY · contact PI
Eval. of Minocycline as a Microglia Inhibitor in Tx of CRVO and BRVO$68,258
ZIA · FY2017 · EY · contact PI
Pilot Study to Evaluate Oral Minocycline in the Treatment of Cystoid Macular Edema Associated with Retinitis Pigmentosa$55,132
ZIA · FY2017 · EY · contact PI
Evaluation of Dextromethorphan as a Microglia Inhibitor in the treatment of DME$28,878
ZIA · FY2017 · EY · contact PI
Genotype - phenotype Study of Patients with Plaquenil-induced Retinal Toxicity,$28,878
ZIA · FY2017 · EY · contact PI
Eval. of Minocycline as a Microglia Inhibitor in Tx of CRVO and BRVO$94,462
ZIA · FY2016 · EY · contact PI
Longitudinal Investigation of Dark Adaptation in Participants with AMD$76,094
ZIA · FY2016 · EY · contact PI
Pilot Study to Evaluate Oral Minocycline in the Treatment of Cystoid Macular Edema Associated with Retinitis Pigmentosa$55,103
ZIA · FY2016 · EY · contact PI
Evaluation of Dextromethorphan as a Microglia Inhibitor in the treatment of DME$28,863
ZIA · FY2016 · EY · contact PI
Genotype - phenotype Study of Patients with Plaquenil-induced Retinal Toxicity,$28,863
ZIA · FY2016 · EY · contact PI
Eval. of Minocycline as a Microglia Inhibitor in Tx of CRVO and BRVO$293,822
ZIA · FY2015 · EY · contact PI
Longitudinal Investigation of Dark Adaptation in Participants with AMD$131,632
ZIA · FY2015 · EY · contact PI
Eval. of Minocycline as a Microglia Inhibitor in Tx of Diabetic Macular Edema$61,115
ZIA · FY2015 · EY · contact PI
Pilot Study to Evaluate Oral Minocycline in the Treatment of Cystoid Macular Edema Associated with Retinitis Pigmentosa$49,362
ZIA · FY2015 · EY · contact PI
Evaluation of Dextromethorphan as a Microglia Inhibitor in the treatment of DME$25,856
ZIA · FY2015 · EY · contact PI
Genotype - phenotype Study of Patients with Plaquenil-induced Retinal Toxicity,$25,856
ZIA · FY2015 · EY · contact PI
Eval. of Minocycline as a Microglia Inhibitor in Tx of CRVO and BRVO$126,076
ZIA · FY2014 · EY · contact PI
Longitudinal Investigation of Dark Adaptation in Participants with AMD$118,802
ZIA · FY2014 · EY · contact PI
Evaluation of Dextromethorphan as a Microglia Inhibitor in the treatment of DME$113,953
ZIA · FY2014 · EY · contact PI
Pilot Study to Evaluate Oral Minocycline in the Treatment of Cystoid Macular Edema Associated with Retinitis Pigmentosa$104,255
ZIA · FY2014 · EY · contact PI
Eval. of Minocycline as a Microglia Inhibitor in Tx of CRVO and BRVO$158,383
ZIA · FY2013 · EY · contact PI
Longitudinal Investigation of Dark Adaptation in Participants with AMD$141,835
ZIA · FY2013 · EY · contact PI
Evaluation of Dextromethorphan as a Microglia Inhibitor in the treatment of DME$120,560
ZIA · FY2013 · EY · contact PI
Eval. of Minocycline as a Microglia Inhibitor in Tx of CRVO and BRVO$175,326
ZIA · FY2012 · EY · contact PI
Longitudinal Investigation of Dark Adaptation in Participants with AMD$136,365
ZIA · FY2012 · EY · contact PI
Evaluation of Dextromethorphan as a Microglia Inhibitor in the treatment of DME$124,189
ZIA · FY2012 · EY · contact PI
Longitudinal Investigation of Dark Adaptation in Participants with AMD$203,225
ZIA · FY2011 · EY · contact PI